Bicycle Therapeutics Plc - ADR

Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display screening platform to identify bicycles. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.

The average of price targets set by Wall Street analysts indicates a potential upside of 77.2% in Bicycle Therapeutics (BCYC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See a 77.22% Upside in Bicycle Therapeutics (BCYC): Can the Stock Really Move This High?

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported recent business progress and financial results for the first quarter ended March 31, 2024. “During the first quarter, we focused on execution across all aspects of our business. We were pleased to initiate our Phase 2/3 Duravelo-2 registrational.

Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the acceptance of two abstracts for poster presentation at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting, taking place May 31-June 4 in Chicago. Poster Presentation Details: Title: Breaking from the paradigm of antibody-d.

Bicycle Therapeutics Announces Two Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on April 9, 2024, at 11 a.m. ET. A live webcast of the fireside chat will be accessible from the Investor section of the company's websi.

Bicycle Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference

AstraZeneca

Bayer AG

Bristol-Myers

Exelixis

Fusion Pharmaceuticals

Eli Lilly

Merck

Novartis

Takeda Pharmaceutical

M&A activity in the biotech/biopharma sector is expected to remain active due to significant cash on Big Pharma's balance sheets, key patent expirations, and declining revenue from Covid related products. The oncology space continues to be a hot and active area for deal volume, with global sales projected to reach $375 billion by 2027. Today, we profile two smaller oncology names that appear to be logical acquisitions for larger concerns that want to expand their oncology footprints.

2 More Potential Biotech Buyout Targets

Bicycle Therapeutics plc results from the phase 1/2 Duravelo-1 study, using BT8009 for the treatment of patients with metastatic urothelial carcinoma, expected in the 2nd half of 2024. Data from BT5528 [Bicycle toxin conjugate tech] and BT7480 [Bicycle tumor-targeted immune cell agonist] clinical candidates targeting solid tumors, expected in the 2nd half of 2024. A data updated on the Bicycle Radio Conjugate technology program is expected in mid-2024.

Bicycle: 2nd Half Of 2024 Data Could Provide Significant Inflection Point

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the acceptance of three abstracts for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place in San Diego on April 5-10. Poster Presentation Details: Title: Bicycle Toxin Conjugates® for the.

Bicycle Therapeutics to Present at the AACR Annual Meeting 2024

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided recent corporate updates. “2023 was a pivotal year for our company, during which we achieved significant progress across our Nectin-4 and EphA2 clinical.

Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 14, 2024, at 10 a.m. ET. A live webcast of the fireside chat will be accessible from the Investor section of the compan.

Bicycle Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, is today hosting a Research & Development (R&D) Day for investors and analysts in New York to provide clinical updates for BT8009, BT7480 and BT5528, and an overview of the company's strategy and pipeline opportunities. The company will also highlight the broad.

Bicycle Therapeutics Provides Data Updates for Three Clinical Programs and Strategy Overview at First R&D Day

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that the company will host its first Research and Development (R&D) Day on Thursday, December 14. The event will take place in New York City from 8 a.m. to 12 p.m. Eastern Time and will be simultaneously webcast. Bicycle Therapeutics executives w.

Bicycle Therapeutics to Host R&D Day on December 14

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the third quarter ended September 30, 2023, and provided recent corporate updates. “In the third quarter, we took important steps toward achieving our goal of quickly getting our novel therapies to those who need them. We are ex.

Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results and Announces Upcoming R&D Day

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that BT8009, the company's lead investigational therapy in development to treat metastatic bladder (urothelial) cancer, has been selected to participate in the Chemistry, Manufacturing and Controls (CMC) Development and Readiness Pilot (CDRP) Program re.

Bicycle Therapeutics Selected to Participate in FDA Program to Expedite Commercial Manufacturing Readiness of BT8009 for Metastatic Bladder Cancer

EDINBURGH and CAMBRIDGE, United Kingdom, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Macomics Ltd, a leader in macrophage drug discovery, announces that it has appointed Kevin Lee Ph.D., MBA as Independent Non-Executive Director.

Macomics Announces the Appointment of Kevin Lee as Independent Non-Executive Director

Bicycle (BCYC) aligns with the FDA on the design of a mid-late-stage registrational study for its bladder cancer drug, BT8009, with the potential to support its accelerated approval. The stock rises 9%.

Bicycle (BCYC) to Begin Pivotal Bladder Cancer Study, Stock Up

Bicycle Therapeutics PLC Sponsored ADR (BCYC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Bicycle Therapeutics PLC Sponsored ADR (BCYC) Surges 9.0%: Is This an Indication of Further Gains?

Bicycle Therapeutics has 14 programs in its pipeline. The company is a clinical-stage biotech.

Why Shares of Bicycle Therapeutics Were Rising on Monday

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the company will proceed with its plan to expedite development of BT8009 for metastatic bladder (urothelial) cancer following recent discussions with the U.S. Food and Drug Administration (FDA). The company has aligned with the FDA on a Phase 2/3 regist.

Bicycle Therapeutics Announces Expedited Development Plan for BT8009 in Metastatic Bladder Cancer

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference in New York on September 12, 2023, at 10:10 a.m. ET. A live webcast of the fireside chat will be accessible in the Investors & Media s.

Bicycle Therapeutics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the second quarter ended June 30, 2023 and provided recent corporate updates. “We have made significant progress in the first half of 2023 executing on our plan to become one of the world's leading solid tumor medicines companie.

Bicycle Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Bicycle Therapeutics is an intriguing play in the drug development space. Using its fully synthetic short peptides, the company has developed two mid-stage oncology assets that have achieved some results of interest in urothelial / ovarian cancers. The company also has numerous potentially lucrative co-development opportunities with the likes of Roche, Novartis, Ionis Pharmaceuticals.

Bicycle Therapeutics: Decent Upside Opportunity, Mid-Stage Data Readouts Due

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the closing on Monday, July 17, 2023 of its underwritten public offering of 6,117,648 American Depositary Shares (“ADSs”), each representing one ordinary share, which includes 1,411,764 ADSs sold upon the underwriters' full exercise of their option.

Bicycle Therapeutics Announces Closing of Public Offering of American Depositary Shares and Non-Voting Ordinary Shares and Full Exercise of Underwriters' Option to Purchase Additional Shares

Bicycle Therapeutics PLC Sponsored ADR (BCYC) Soars 19.3%: Is Further Upside Left in the Stock?

The U.K.-based biotech announced a fresh offering of its ADSes. It's seeking to net around $187 million in proceeds with the issue.

Why Bicycle Therapeutics Stock Raced Ahead Today

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the pricing of an underwritten public offering of 9,411,766 American Depositary Shares (“ADSs”), each representing one ordinary share and, in lieu of ADSs to investors that so choose, non-voting ordinary shares, each at a price to the public of $21.

News for Bicycle Therapeutics Plc - ADR Stock (BCYC)